LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Cempra shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
The investigation concerns whether Cempra and certain of its officers and/or directors violated federal securities laws. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra’s drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. When this news was announced, shares of Cempra fell in value sharply.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
